Latest news with #obesity
Yahoo
18 hours ago
- Health
- Yahoo
After people stop taking GLP-1s, the effects also end, study finds
People who stop taking GLP-1 medications like Wegovy and Zepbound started to regain weight in a short amount of time, a new study suggests. Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called glucagon-like peptide-1 receptor agonists, or GLP-1s, which mimic the GLP-1 hormone that is produced in the gut after eating. It can help produce more insulin, which reduces blood sugar and therefore helps control Type 2 diabetes. It can also interact with the brain and signal a person to feel full, which -- when coupled with diet and exercise -- can help reduce weight in those who are overweight or obese. MORE: Compound versions of GLP-1 drugs for weight loss halted by FDA The team, from Peking University People's Hospital in China, found that most began to regain weight within about two months of stopping treatment. In many cases, that weight gain continued for several months before leveling off. The study was published Tuesday in the journal BMC Medicine. However, Dr. Louis J. Aronne, founder and former chairman of the American Board of Obesity Medicine, told ABC News that doesn't mean the medications failed. In fact, they worked exactly as intended, he said. Aronne, who is also a physician at Weill Cornell Medicine, said the findings are consistent with what happens when treatment ends for other chronic conditions. "What happens after stopping an obesity medication is exactly what happens after stopping a diabetes, cholesterol-lowering, or a blood pressure medication," he told ABC News. "The effect of the medicine goes away, and people tend to go back to where they started." Patients who had taken GLP-1s tended to lose more weight during treatment, which meant they had more weight to gain back afterward. 'It's not that the medicine didn't work,' Aronne said. 'It's that they lost more weight, so they had more weight to regain.' Even participants who continued healthy eating and exercise habits after stopping medication experienced weight gain. MORE: Compound versions of GLP-1 drugs for weight loss halted by FDA That doesn't mean those efforts weren't worthwhile, Aronne further explained, but rather that obesity is a chronic disease with complex biological drivers. "You wouldn't stop insulin and expect a person's blood sugar to stay low," he said. The researchers noted several limitations, including a small number of included studies and a focus on weight and BMI without tracking other health markers like blood sugar or cholesterol. These medications may not right for everyone, and decisions about starting or stopping should be made with your doctor, according to MedlinePlus. People with certain medical conditions, including a history of pancreatitis or thyroid cancer, may not be good candidates, and should speak with their doctor to decide what management strategies are right for them. Alexandra-Elise Dakaud Patterson, MD, MS, is a general surgery resident at University of Toledo Medical Center and a member of the ABC News Medical Unit. Solve the daily Crossword
Gizmodo
20 hours ago
- Health
- Gizmodo
This Experimental Weight Loss Drug Works Without the Nausea or Vomiting
What if you could lose weight with a drug that won't make you lose your lunch at the same time? New research shows it might be possible. Scientists at the University of Pennsylvania, the University of Kentucky, and other institutions say they've found a potentially novel way to suppress people's appetite and treat obesity—without causing the nausea or vomiting commonly experienced with semaglutide (the active ingredient in Ozempic and Wegovy). In early animal experiments, the team's experimental drug appears to be working as intended. Semaglutide and similar drugs mimic the natural GLP-1 hormone, which is important to regulating our insulin production and hunger. As effective as these medications are at helping people lose weight, they have their tradeoffs—most notably a high chance of gastrointestinal side effects. So there's clearly still a need for improved obesity treatments, according to lead study author Caroline Geisler, an assistant professor at UKY's College of Pharmacy. This Simple Strategy Could Curb One of Semaglutide's Worst Side Effects Geisler and her team have been exploring one particular strategy for treating obesity, involving a protein called octadecaneuropeptide, or ODN. ODN is produced by the brain's glia, specialized cells that support neurons. But glia aren't just the brain's support troops, and ODN seems to be important to controlling our sense of hunger. 'Now we know that [glia] play a large role in sensing and communicating the status of the body, and we hope that by targeting a glial signaling molecule, we can engage many energy-regulating pathways in the brain and avoid the side effects of nausea and vomiting,' Geisler told Gizmodo. The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats lost weight and improved their blood sugar control. And when they blocked ODN signaling in rats, the animals exhibited a weaker response to GLP-1 treatment (suggesting its effects are at least partly tied to ODN). Finally, they indirectly dosed mice, rats, and shrews with an experimental drug derived from ODN, called TDN. In mice, TDN improved blood sugar control; in rats, it caused weight loss without nausea or vomiting; and in shrews (animals commonly used to test motion sickness and vomiting), the drug triggered no puking at all. The drug also appeared to not have any noticeable effects on the animals' heart rate, movement, and temperature. 'This paper shows for the first time that giving a smaller version of ODN in the periphery is still effective to improve body weight and metabolic control without side effects,' Geisler said. The team's findings, published Wednesday in Science Translational Medicine, are only a proof of concept for now. There remain many questions about exactly how ODN works in the brain to tamp down our appetite and control blood sugar. It's also possible that ODN-based drugs can be further optimized for medical use, though TDN seemed to produce steady weight loss in animals for at least over a week without waning. Still, the researchers are hopeful this potential new drug class can match or even surpass the effectiveness of today's GLP-1 therapies while being less of a hassle to take. And they're now planning to develop such drugs for testing in people. 'We have an optimistic timeline that we could be ready to start clinical trials within 2 years,' Geisler said. The Best Obesity Drugs Aren't Even Here Yet The study researchers are hardly the only ones working to introduce the next generation of improved obesity and diabetes treatments. But it's likely plenty of people would sign up for a safe weight loss drug that comes without the need for a barf bag.
Medical News Today
21 hours ago
- Health
- Medical News Today
What happens when you stop using Wegovy?
Weight regain and increased appetite are common after stopping Wegovy (semaglutide). Understanding the effects of stopping treatment is important to manage long-term weight loss expectations. Your doctor can help you stop Wegovy while still maintaining your weight management goals. Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) agonist used for weight loss and weight management and to reduce the risk of major cardiovascular events. Stopping Wegovy, especially suddenly, can affect your body and weight management reading to learn what happens when you stop Wegovy to stop WegovyWegovy is meant to be a long-term medication for certain people with obesity or overweight. If you need to stop taking the medication for any reason, be sure to talk with your doctor about how to safely stop your treatment. You should not stop taking Wegovy suddenly, or 'cold turkey.'Your doctor can provide guidance on stopping Wegovy to help reduce the risk of certain effects. They can also adjust your diet and exercise regimen and help monitor your progress after stopping treatment. Following a personalized plan can help maintain the progress you achieved with effects of stopping WegovyStopping Wegovy treatment can have different effects. This is because GLP-1 levels will decrease after stopping the medication. And your GLP-1 levels will return to what's normal for your is a hormone that's involved in several processes, including blood sugar and insulin regulation, management of appetite and satiety, and protective cardiovascular effects. The active ingredient in Wegovy, semaglutide, mimics the effects of GLP-1, which promotes weight loss and reduced appetite, among other effects.»Learn more about how Wegovy regainIf you've lost weight with Wegovy, stopping treatment may cause weight regain. This is sometimes called 'Ozempic rebound'. (Ozempic contains semaglutide, the same active ingredient as Wegovy, but it comes in smaller doses and is approved for different uses. Unlike Wegovy, Ozempic is not approved by the Food and Drug Administration [FDA] for weight loss or weight management.)In a 2021 clinical trial, adults with overweight or obesity who used Wegovy for 20 weeks and then switched to a placebo (a treatment with no active drug) had a weight increase of nearly 7%. This was in comparison to adults who continued Wegovy treatment after 20 weeks and lost nearly 8% of their weight over the next 48 weeks of in a 2022 clinical trial, adults who stopped taking Wegovy after 68 weeks of Wegovy treatment regained two-thirds of the weight they lost within a year of stopping to these effects, Wegovy is typically taken long-term to maintain weight loss or weight management. If you have concerns about weight regain after stopping Wegovy, talk with your doctor. They can help determine the best course of action for of cardiovascular benefits and increased blood sugarStopping treatment with Wegovy may affect your risk of experiencing major cardiovascular events, such as heart attack or stroke. For people taking Wegovy to reduce the risk of these events, the risk may return to original levels when Wegovy treatment was shown in a 2022 clinical trial, in which most cardiovascular benefits that adults experienced with Wegovy went back to baseline after stopping treatment for 1 year. (Here, baseline refers to the original level of cardiovascular risk before Wegovy treatment began.)If you stop treatment with Wegovy, you may experience the following cardiovascular symptoms: increased blood pressureincreased cholesterol levelsirregular heartbeatnausea and vomitingheadacheschest paindizzinessdifficulty breathingnosebleedsbuzzing in the earsvision changesconfusionanxietyAlso in the same study, prediabetes returned in some people who used Wegovy for 68 weeks and then stopped treatment. So if you have high blood sugar levels and stop using Wegovy, symptoms of your high blood sugar levels may return. These may include:weaknessfatigueblurry visionsweatinggum bleeding or skin infections that keep coming backslow wound healingDue to these effects, your doctor will likely suggest other ways to manage your risk of cardiovascular problems and high blood sugar levels. They may recommend taking certain other medications or other lifestyle withdrawal symptomsWithdrawal refers to experiencing side effects after you stop taking a substance that your body has become dependent on. Wegovy hasn't been specifically reported to cause dependence or withdrawal. (With dependence, your body needs a substance in order to function as usual.) However, people who stop Wegovy may experience certain symptoms due to their GLP-1 levels going back to normal. These symptoms may include:increased appetitereduced feeling of fullness changes in moodchanges in energy levels If you have concerns about these symptoms, talk with your doctor. They can recommend ways to manage them effectively while transitioning off Wegovy the weight off after stopping WegovyAfter stopping Wegovy, it's important to have a plan in place to help prevent weight gain or continue your weight management efforts. This can also help your overall health. Ways to help prevent weight gain include: maintaining a balanced diet with nutrient-dense foodssticking with your exercise routine or adjusting it based on your doctor's recommendationsstaying hydrated with water or low calorie beveragesgetting enough sleep managing stress levels monitoring your weight periodicallyYou can work with your doctor to develop a plan to keep the weight off after stopping Wegovy. Preliminary research has also shown that people taking semaglutide maintained weight loss by tapering (slowly lowering) their dosage before completely stopping treatment. So to help prevent weight regain, your doctor may slowly lower your Wegovy dosage before stopping the what happens when you stop using Wegovy is important to help prevent weight gain, continue long-term weight management efforts, and maintain cardiovascular health. By working closely with your doctor and adopting certain lifestyle habits, it's possible to safely and effectively stop Wegovy Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Yahoo
a day ago
- Health
- Yahoo
A new genetic test may be able to predict obesity in early childhood. What to know
More than 2 out of 5 adults in the U.S. are considered obese, according to the Centers for Disease Control and Prevention. But what if there was a way to test children to find out if they're at higher risk for contracting the chronic condition while still having time to change their lifestyle? In a study published July 21 in the journal Nature Medicine, more than 600 scientists from 500 institutions worldwide compiled genetic data from more than 5 million people. Using data collected by The Genetic Investigation of ANthropometric Traits (GIANT) consortium – an international collaboration of human genetics researchers and 23andMe – a genetic measure known as polygenic risk scores (PGS) was developed to help identify children at higher risk of developing obesity in adulthood. Obesity is a serious, common and costly chronic condition characterized by excessive body fat, often defined as a Body Mass Index (BMI) of 30 or greater. The American Medical Association considers it a significant public health concern, as it increases the risk of numerous conditions, including diabetes and heart disease. What does the study say? Researchers developed ancestry-specific and multi-ancestry polygenic risk scores and found they were about twice as effective as the risk assessments doctors currently use. For people with European ancestry, the newly developed risk score accounted for about 17.6% of a person's risk of developing a high BMI in adulthood. About 70% of participants whose genetic data was compiled in the study had predominantly European ancestry, 14.4% had Hispanic ethnicity with typically mixed ancestries, 8.4% had predominantly East Asian ancestry, 4.6% had predominantly African ancestry and 1.5% were of predominantly South Asian origin, according to the research. Ruth Loos, a co-author of the study, is a professor at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. In an interview with NBC News, she explained, 'Obesity is not only about genetics, so genetics alone can never accurately predict obesity.' 'For the general obesity that we see all over the world, we need other factors, such as lifestyle, that need to be part of the predictions,' added Loos. Obesity increases the risk of nearly 200 diseases and can cause serious health conditions like asthma, strokes, Type 2 diabetes and some types of cancers. It was a risk factor in 3.7 million deaths in 2021. Globally, obesity in adults has more than doubled since 1990, with adolescent rates quadrupling, the World Health Organization reported. How can communities address obesity? Ensuring access to healthy foods, safe places for physical activity, stigma-free obesity prevention and treatment programs, and evidence-based health care services such as medication and surgery are examples of how to address and prevent obesity, according to the CDC. Director of the CDC's National Center for Chronic Disease Prevention and Health Promotion, Karen Hacker previously told USA TODAY that there is no singular approach to addressing the health concern. 'Obesity is a disease caused by many factors, including eating patterns, physical activity levels, sleep routines, genetics and certain medications. This means that there is no one-size-fits-all approach, Hacker said. 'However, we know the key strategies that work include addressing the underlying social determinants of health, such as access to health care, healthy and affordable food and safe places for physical activity,' Hacker added. This article originally appeared on USA TODAY: A new genetic test may be able to predict obesity in early childhood Solve the daily Crossword
Yahoo
a day ago
- Business
- Yahoo
ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update
Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current cash position secures runway until Q2 2026 LYON, France, July 23, 2025--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2025 and provides a business update. "Over the past six months, significant progress has been achieved on both AdoShell® and BioChaperone® CagriSema. Meanwhile, the arrival of semaglutide biosimilars accross many countries in 2026 presents a new opportunity for AdOral® Sema, broadening the field of possible partners. For M1Pram, we are continuing our discussions to finance and launch a Phase 2b study in the USA. Thanks to a healthy cash position, we are maintaining our ambitious business objectives for the coming months." says Olivier Soula, Chief Executive Officer of Adocia. "The US$10 million milestone payment from our Chinese partner, triggered by the completion of the first Phase 3 study of Ultra-Rapid Insulin, BioChaperone® Lispro, as well as the 2024 Research Tax Credit of €2.8 million were received shortly after the closing of the second quarter, securing our cash runway until Q2 2026. Furthermore, the quality and maturity of our pipeline of products open up new partnership opportunities that we are actively exploring." added Mathieu-William Gilbert, CFO-COO of Adocia. Second quarter 2025 financial results Financial highlights for the quarter include the following: DETAIL OF THE REVENUE In thousands of euros, IFRS standards (unaudited) 06/30/2025(3 months) 06/30/2024(3 months) 06/30/2025(6 months) 06/30/2024(6 months) Licensing revenues 0 0 0 0 Research and collaboration agreements 445 0 1,031 0 Revenue 445 0 1,031 0 The revenue of €1 million for the first semester 2025 is mainly related to the feasibility study on the AdOral® technology, applied to a novel incretin for an undisclosed partner. Net Cash Position The Company's cash position stood at €7.1 million as of June 30, 2025, compared to €7.5 million as of December 31, 2024. This position includes €9.7 million received from the private placement completed in February 20251. The cash burn related to activities in the first half of 2025 amounted to €11.8 million, compared to €10.6 million in the first half of 2024 (excluding financing). Net financial debt (excluding IFRS 16 impacts), consisting exclusively of state-guaranteed loans (PGE), amounted to €3.3 million as of June 30, 2025, down €0.6 million compared to March 31, 2025, following the repayments made during this quarter. The maturity of these loans remains up to end August 2026. The cash position as of June 30, 2025, of €7.1 million, together with the US$10 million received from Tonghua Dongbao and the €2.8 million in connection with the 2024 Research Tax Credit, both received in July 2025, allows the Company to fund its activities until the second quarter of 2026, it being specified that this cash runway does not take into account other potential revenues generated by existing or future partnerships. Second quarter 2025 Highlights BioChaperone® Lispro – partnered with Tonghua Dongbao Partner Tonghua Dongbao initiated two Phase 3 studies with Ultra-Rapid Insulin BioChaperone® Lispro with about 1,500 people with Type 1 or Type 2 diabetes in 2022. The last patient in the Type 1 Diabetes study was dosed in January 2025, leading to the expected announcement of top-line results in mid-2025. Assuming successful Phase 3 results, Tonghua Dongbao could submit Ultra-Rapid Insulin BioChaperone® Lispro for Chinese regulatory review in 2025. The granting of Marketing Authorization would lead to an additional milestone payment of US$20 million and double-digit royalties on sales to Adocia. BioChaperone® GLP-1 – Amylin / BioChaperone® CagriSema The preclinical development of BioChaperone® CagriSema, which offers a stable combination of cagrilintide and semaglutide in the same delivery chamber, continues as planned. Data generated to date are promising regarding its commercial and manufacturing benefits over the combination of cagrilintide and semaglutide, currently being developed by Novo Nordisk, which requires each peptide to be in separate chambers of a single-use pen device. BioChaperone® CagriSema is expected to offer significant manufacturing advantages, such as enabling it to be included in existing multi-use pen platforms. Proof of stability, safety and efficacy is well established, and the product is subject to appropriate intellectual property protection. The Company's priority is to secure a licensing agreement for this product. M1Pram M1Pram is a fixed combination of insulin and amylin analogs aimed at addressing the unmet medical need of obesity in insulin-dependent individuals. Adocia granted Sanofi an exclusive right to negotiate a partnership on M1Pram for €10 million2. Discussions about this partnership are still ongoing. A Phase 2b clinical program in the United States, involving 140 patients with Type 1 diabetes and a BMI3>30kg/m², has been prepared. Adocia has completed the manufacturing of clinical batches of M1Pram. The launch of this clinical trial is conditional on the signing of an agreement on the product. AdoShell® Islets The innovative AdoShell® technology platform is designed to implant human insulin-secreting cells from either deceased donors (islets of Langherans) or stem cells to provide a cure for Type 1 diabetes without immunosuppression. Adocia presented its latest preclinical data on AdoShell® technology at two scientific conferences in June: the American Diabetes Association's (ADA) 85th Scientific Sessions & the International Pancreas and Islet Transplant Association (IPITA) 2025 World Congress. The results demonstrated the major progress achieved with the AdoShell® platform. The implant has been successfully adapted to human scale. In addition, the in vitro and in vivo maturation of islets derived from immature stem cells in AdoShell® was demonstrated. Finally, the long-term functionality and efficacy of these encapsulated islets were confirmed in vivo. Preparatory work to submit a clinical trial application to the regulator for AdoShell® with human islets for 2025 remains on track. AdOral® Adocia has developed an oral peptide delivery technology, enabling the transition from injectable to oral forms, and has achieved promising preclinical results delivering semaglutide (GLP-1) orally. Data on AdOral® Sema was presented at the ATTD 2025 conference (18th International Conference on Advanced Technologies & Treatments for Diabetes, 19-22 March, 2025, Amsterdam, The Netherlands). From 2026, semaglutide will be off-patent in many countries, and many companies are preparing to launch biosimilars of Ozempic. This situation creates an opportunity for AdOral®, a patented technology for the oral delivery of semaglutide for diabetes and obesity. The AdOral® technology is currently undergoing an R&D collaboration agreement for an application to a novel incretin. All costs related to this agreement are covered by the partner. AdoGel® Designed to enable long-term peptide delivery, AdoGel® is currently being studied for a once-monthly dosing of semaglutide (GLP-1). GLP-1, a market that generated over US$53 billion in global revenue in 2024, is almost exclusively formulated for weekly injections4. AdoGel®'s unique technology could enable monthly or even quarterly injections. New preclinical results were selected for a poster presentation at the ATTD 2025 conference (18th International Conference on Advanced Technologies & Treatments for Diabetes, 19-22 March, 2025, Amsterdam, The Netherlands) and for an oral presentation at the SFD 2025 congress (Congress of the Société Francophone du Diabète, April 1-4, 2025, Paris, France). Adocia has decided to put the AdoGel® project on hold in order to concentrate its technical efforts on AdoShell®, BioChaperone® CagriSema, and AdOral®. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. 1 Press Releases, February 26, 2025, ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026; and February 28, 2025, ADOCIA Announces the Settlement-Delivery of its €9.7Million Private Placement2 Press Release, July 5, 2023, ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing3 BMI stands for Body Mass Index, calculated as the mass of a person in Kg, divided by the square of its height in meters4 Global Data, based on consolidated sales View source version on Contacts Adocia Olivier Soula CEOcontactinvestisseurs@ +33 (0)4 72 610 Ulysse CommunicationAdocia Press & Investor Relations Bruno ArabianNicolas Entzadocia@ + 33 (0)6 87 88 47 26 Sign in to access your portfolio
